Also trades as: FRX.TO (TSX) · $vol 0M
FENC NASDAQ
Fennec Pharmaceuticals Inc.
1W: -1.2%
1M: -4.3%
3M: +2.1%
YTD: +32.2%
1Y: +13.3%
3Y: +47.1%
5Y: +16.1%
$10.62
+0.47 (+4.63%)
After Hours: $10.97 (+0.35, +3.30%)
Weekly Expected Move ±5.8%
$9
$9
$10
$11
$11
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' -3.46.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$355.9M
52W Range5.65-13.25
Volume115,940
Avg Volume201,024
Beta1.10
Dividend—
Analyst Ratings
Company Info
CEOJeffrey S. Hackman
Employees35
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-15
Websitefennecpharma.com
68 TW Alexander Drive
Research Triangle Park, NC 27709
US
Research Triangle Park, NC 27709
US
919 636 4530
About Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical firm. Its leading investigational drug in clinical development is PEDMARK, a specialized formulation of sodium thiosulfate. This treatment is designed to shield young cancer patients from hearing damage (ototoxicity) that can be induced by platinum-based chemotherapy. The company, which was founded in 1996, previously operated under the name Adherex Technologies Inc. before officially rebranding as Fennec Pharmaceuticals Inc. in September 2014. Its corporate headquarters are situated in Research Triangle Park, North Carolina.
Latest News
Fennec Pharmaceuticals Announces Oral Presentation of Detailed Results from Investigator-Initiated Phase 2 STS-J01 Clinical Study of Pedmark® in Japan at SIOP 2026
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
Adherex Technologies Inc. (FENC) Beats Q2 Earnings and Revenue Estimates
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Sayad Pierre Sargis | A-Award | 3,846 | $5.53 | 2026-10-12 |
| Hackman Jeffrey S. | A-Award | 2,224 | $5.53 | 2026-10-12 |
| Evans Terry L | A-Award | 2,326 | $5.53 | 2026-10-12 |
| Cioffi Christiana Ma | A-Award | 3,946 | $5.53 | 2026-10-12 |
| Andrade Robert | A-Award | 3,846 | $5.53 | 2026-10-12 |